ArticlePloS one2016
Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review.British journal of cancer · 2022Pooled it
- Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? : A Systematic Review.Annals of internal medicine · 2021Pooled it
- Pooled it
- Medical Device Industry Payments and Utilization of Corresponding Devices.JAMA network open · 2026Article
- Surgical society committee members disclosure of conflict of interest: show me the money.Surgical endoscopy · 2026Article
- Associations between pharmaceutical industry interactions with physicians and chronic nonmalignant pain management prescribing practices: a systematic review.Cost effectiveness and resource allocation : C/E · 2026Review
- Subconscious value influences on science.Studies in history and philosophy of science · 2025Article
- The Imperative of Regulation: The Co-creation of a Medical and Non-medical US Opioid Crisis.Psychoactives · 2023Article
- Industry payments to family medicine residents in Portugal: a descriptive analysis of the national transparency database.BMJ open · 2023Article
- Article
- The Role of Physician Networks and Receipt of Opioid-Related Payments.Journal of general internal medicine · 2023Article
- Off-Label Use vs Off-Label Marketing of Drugs: Part 1: Off-Label Use-Patient Harms and Prescriber Responsibilities.JACC. Basic to translational science · 2023Article
- Industry Payments to Physicians Are Kickbacks. How Should Stakeholders Respond?Journal of health politics, policy and law · 2022Article
- Evaluation of Industry Payments to US Advanced Practice Clinicians in 2021.JAMA network open · 2022Article
- Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019.International journal of environmental research and public health · 2022Article
- The Invisible Hand of Industry.Clinical obstetrics and gynecology · 2022Article
- Associations Between Industry Payments to Physicians for Antiplatelet Drugs and Utilization of Cardiac Procedures and Stents.Journal of general internal medicine · 2022Article
- Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide.Urology · 2022Article
- Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014-2017.Journal of the National Comprehensive Cancer Network : JNCCN · 2021Article
- Orthopaedic Trauma Surgeons' Financial Relationships With Industry: An Analysis of the Sunshine Act Reporting of Physician Open Payments From 2014 to 2019.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe U.S. Physician Payments Sunshine Act mandates the reporting of payments or items of value received by physicians from drug, medical device, and biological agent manufacturers. The impact of these payments on physician prescribing has not been examined at large scale.
methodsWe linked public Medicare Part D prescribing data and Sunshine Act data for 2013. Physician payments were examined descriptively within specialties, and then for association with prescribing costs and patterns using regression models. Models were adjusted for potential physician-level confounding features, including sex, geographic region, and practice size.
resultsAmong 725,169 individuals with Medicare prescribing data, 341,644 had documented payments in the OPP data (47.1%). Among all physicians receiving funds, mean payment was $1750 (SD $28336); median was $138 (IQR $48-$394). Across the 12 specialties examined, a dose-response relationship was observed in which greater payments were associated with greater prescribing costs per patient. In adjusted regression models, being in the top quintile of payment receipt was associated with incremental prescribing cost per patient ranging from $27 (general surgery) to $2931 (neurology). Similar associations were observed with proportion of branded prescriptions written.
conclusionsWhile distribution and amount of payments differed widely across medical specialties, for each of the 12 specialties examined the receipt of payments was associated with greater prescribing costs per patient, and greater proportion of branded medication prescribing. We cannot infer a causal relationship, but interventions aimed at those physicians receiving the most payments may present an opportunity to address prescribing costs in the US.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.